Kidney Cancer Medicine Market, Global Outlook and Forecast 2022-2028

March 2022 | 100 pages | ID: K6A6C9440BA2EN
Market Monitor Global

Abstracts

Kidney cancer -- also called renal cancer -- is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Almost all kidney cancers first appear in the lining of tiny tubes (tubules) in the kidney. This type of kidney cancer is called renal cell carcinoma.

Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.

This report contains market size and forecasts of Kidney Cancer Medicine in Global, including the following market information:

Global Kidney Cancer Medicine Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Kidney Cancer Medicine market was valued at 5255.3 million in 2021 and is projected to reach US$ 6545.8 million by 2028, at a CAGR of 3.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Monoclonal Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Kidney Cancer Medicine include Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis and Takeda, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Kidney Cancer Medicine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Kidney Cancer Medicine Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Kidney Cancer Medicine Market Segment Percentages, by Type, 2021 (%)

• Monoclonal Antibody
• mTOR Inhibitors
• Kinase Inhibitors
• Other

Global Kidney Cancer Medicine Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Kidney Cancer Medicine Market Segment Percentages, by Application, 2021 (%)

• Renal Cell Carcinoma (RCC)
• Transitional Cell Carcinoma (TCC)

Global Kidney Cancer Medicine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Kidney Cancer Medicine Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Kidney Cancer Medicine revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Kidney Cancer Medicine revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• Bristol-Myers Squibb
• Roche
• GSK
• Novartis
• Bayer
• Merck & Co.
• Exelixis
• Takeda
• Eisai
• CTTQ
• AVEO Oncology
• Everest Pharm
• Cipla
• NATCO
• Beacon Pharma
• SAMARTH

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Kidney Cancer Medicine Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Kidney Cancer Medicine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL KIDNEY CANCER MEDICINE OVERALL MARKET SIZE

2.1 Global Kidney Cancer Medicine Market Size: 2021 VS 2028
2.2 Global Kidney Cancer Medicine Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Kidney Cancer Medicine Players in Global Market
3.2 Top Global Kidney Cancer Medicine Companies Ranked by Revenue
3.3 Global Kidney Cancer Medicine Revenue by Companies
3.4 Top 3 and Top 5 Kidney Cancer Medicine Companies in Global Market, by Revenue in 2021
3.5 Global Companies Kidney Cancer Medicine Product Type
3.6 Tier 1, Tier 2 and Tier 3 Kidney Cancer Medicine Players in Global Market
  3.6.1 List of Global Tier 1 Kidney Cancer Medicine Companies
  3.6.2 List of Global Tier 2 and Tier 3 Kidney Cancer Medicine Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Kidney Cancer Medicine Market Size Markets, 2021 & 2028
  4.1.2 Monoclonal Antibody
  4.1.3 mTOR Inhibitors
  4.1.4 Kinase Inhibitors
  4.1.5 Other
4.2 By Type - Global Kidney Cancer Medicine Revenue & Forecasts
  4.2.1 By Type - Global Kidney Cancer Medicine Revenue, 2017-2022
  4.2.2 By Type - Global Kidney Cancer Medicine Revenue, 2023-2028
  4.2.3 By Type - Global Kidney Cancer Medicine Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Kidney Cancer Medicine Market Size, 2021 & 2028
  5.1.2 Renal Cell Carcinoma (RCC)
  5.1.3 Transitional Cell Carcinoma (TCC)
5.2 By Application - Global Kidney Cancer Medicine Revenue & Forecasts
  5.2.1 By Application - Global Kidney Cancer Medicine Revenue, 2017-2022
  5.2.2 By Application - Global Kidney Cancer Medicine Revenue, 2023-2028
  5.2.3 By Application - Global Kidney Cancer Medicine Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Kidney Cancer Medicine Market Size, 2021 & 2028
6.2 By Region - Global Kidney Cancer Medicine Revenue & Forecasts
  6.2.1 By Region - Global Kidney Cancer Medicine Revenue, 2017-2022
  6.2.2 By Region - Global Kidney Cancer Medicine Revenue, 2023-2028
  6.2.3 By Region - Global Kidney Cancer Medicine Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Kidney Cancer Medicine Revenue, 2017-2028
  6.3.2 US Kidney Cancer Medicine Market Size, 2017-2028
  6.3.3 Canada Kidney Cancer Medicine Market Size, 2017-2028
  6.3.4 Mexico Kidney Cancer Medicine Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Kidney Cancer Medicine Revenue, 2017-2028
  6.4.2 Germany Kidney Cancer Medicine Market Size, 2017-2028
  6.4.3 France Kidney Cancer Medicine Market Size, 2017-2028
  6.4.4 U.K. Kidney Cancer Medicine Market Size, 2017-2028
  6.4.5 Italy Kidney Cancer Medicine Market Size, 2017-2028
  6.4.6 Russia Kidney Cancer Medicine Market Size, 2017-2028
  6.4.7 Nordic Countries Kidney Cancer Medicine Market Size, 2017-2028
  6.4.8 Benelux Kidney Cancer Medicine Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Kidney Cancer Medicine Revenue, 2017-2028
  6.5.2 China Kidney Cancer Medicine Market Size, 2017-2028
  6.5.3 Japan Kidney Cancer Medicine Market Size, 2017-2028
  6.5.4 South Korea Kidney Cancer Medicine Market Size, 2017-2028
  6.5.5 Southeast Asia Kidney Cancer Medicine Market Size, 2017-2028
  6.5.6 India Kidney Cancer Medicine Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Kidney Cancer Medicine Revenue, 2017-2028
  6.6.2 Brazil Kidney Cancer Medicine Market Size, 2017-2028
  6.6.3 Argentina Kidney Cancer Medicine Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Kidney Cancer Medicine Revenue, 2017-2028
  6.7.2 Turkey Kidney Cancer Medicine Market Size, 2017-2028
  6.7.3 Israel Kidney Cancer Medicine Market Size, 2017-2028
  6.7.4 Saudi Arabia Kidney Cancer Medicine Market Size, 2017-2028
  6.7.5 UAE Kidney Cancer Medicine Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Kidney Cancer Medicine Major Product Offerings
  7.1.4 Pfizer Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Key News
7.2 Bristol-Myers Squibb
  7.2.1 Bristol-Myers Squibb Corporate Summary
  7.2.2 Bristol-Myers Squibb Business Overview
  7.2.3 Bristol-Myers Squibb Kidney Cancer Medicine Major Product Offerings
  7.2.4 Bristol-Myers Squibb Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.2.5 Bristol-Myers Squibb Key News
7.3 Roche
  7.3.1 Roche Corporate Summary
  7.3.2 Roche Business Overview
  7.3.3 Roche Kidney Cancer Medicine Major Product Offerings
  7.3.4 Roche Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.3.5 Roche Key News
7.4 GSK
  7.4.1 GSK Corporate Summary
  7.4.2 GSK Business Overview
  7.4.3 GSK Kidney Cancer Medicine Major Product Offerings
  7.4.4 GSK Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.4.5 GSK Key News
7.5 Novartis
  7.5.1 Novartis Corporate Summary
  7.5.2 Novartis Business Overview
  7.5.3 Novartis Kidney Cancer Medicine Major Product Offerings
  7.5.4 Novartis Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.5.5 Novartis Key News
7.6 Bayer
  7.6.1 Bayer Corporate Summary
  7.6.2 Bayer Business Overview
  7.6.3 Bayer Kidney Cancer Medicine Major Product Offerings
  7.6.4 Bayer Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.6.5 Bayer Key News
7.7 Merck & Co.
  7.7.1 Merck & Co. Corporate Summary
  7.7.2 Merck & Co. Business Overview
  7.7.3 Merck & Co. Kidney Cancer Medicine Major Product Offerings
  7.7.4 Merck & Co. Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.7.5 Merck & Co. Key News
7.8 Exelixis
  7.8.1 Exelixis Corporate Summary
  7.8.2 Exelixis Business Overview
  7.8.3 Exelixis Kidney Cancer Medicine Major Product Offerings
  7.8.4 Exelixis Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.8.5 Exelixis Key News
7.9 Takeda
  7.9.1 Takeda Corporate Summary
  7.9.2 Takeda Business Overview
  7.9.3 Takeda Kidney Cancer Medicine Major Product Offerings
  7.9.4 Takeda Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.9.5 Takeda Key News
7.10 Eisai
  7.10.1 Eisai Corporate Summary
  7.10.2 Eisai Business Overview
  7.10.3 Eisai Kidney Cancer Medicine Major Product Offerings
  7.10.4 Eisai Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.10.5 Eisai Key News
7.11 CTTQ
  7.11.1 CTTQ Corporate Summary
  7.11.2 CTTQ Business Overview
  7.11.3 CTTQ Kidney Cancer Medicine Major Product Offerings
  7.11.4 CTTQ Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.11.5 CTTQ Key News
7.12 AVEO Oncology
  7.12.1 AVEO Oncology Corporate Summary
  7.12.2 AVEO Oncology Business Overview
  7.12.3 AVEO Oncology Kidney Cancer Medicine Major Product Offerings
  7.12.4 AVEO Oncology Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.12.5 AVEO Oncology Key News
7.13 Everest Pharm
  7.13.1 Everest Pharm Corporate Summary
  7.13.2 Everest Pharm Business Overview
  7.13.3 Everest Pharm Kidney Cancer Medicine Major Product Offerings
  7.13.4 Everest Pharm Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.13.5 Everest Pharm Key News
7.14 Cipla
  7.14.1 Cipla Corporate Summary
  7.14.2 Cipla Business Overview
  7.14.3 Cipla Kidney Cancer Medicine Major Product Offerings
  7.14.4 Cipla Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.14.5 Cipla Key News
7.15 NATCO
  7.15.1 NATCO Corporate Summary
  7.15.2 NATCO Business Overview
  7.15.3 NATCO Kidney Cancer Medicine Major Product Offerings
  7.15.4 NATCO Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.15.5 NATCO Key News
7.16 Beacon Pharma
  7.16.1 Beacon Pharma Corporate Summary
  7.16.2 Beacon Pharma Business Overview
  7.16.3 Beacon Pharma Kidney Cancer Medicine Major Product Offerings
  7.16.4 Beacon Pharma Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.16.5 Beacon Pharma Key News
7.17 SAMARTH
  7.17.1 SAMARTH Corporate Summary
  7.17.2 SAMARTH Business Overview
  7.17.3 SAMARTH Kidney Cancer Medicine Major Product Offerings
  7.17.4 SAMARTH Kidney Cancer Medicine Revenue in Global Market (2017-2022)
  7.17.5 SAMARTH Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Kidney Cancer Medicine Market Opportunities & Trends in Global Market
Table 2. Kidney Cancer Medicine Market Drivers in Global Market
Table 3. Kidney Cancer Medicine Market Restraints in Global Market
Table 4. Key Players of Kidney Cancer Medicine in Global Market
Table 5. Top Kidney Cancer Medicine Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Kidney Cancer Medicine Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Kidney Cancer Medicine Revenue Share by Companies, 2017-2022
Table 8. Global Companies Kidney Cancer Medicine Product Type
Table 9. List of Global Tier 1 Kidney Cancer Medicine Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Kidney Cancer Medicine Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Kidney Cancer Medicine Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Kidney Cancer Medicine Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Kidney Cancer Medicine Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Kidney Cancer Medicine Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Kidney Cancer Medicine Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Kidney Cancer Medicine Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Kidney Cancer Medicine Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Kidney Cancer Medicine Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Kidney Cancer Medicine Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Kidney Cancer Medicine Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Kidney Cancer Medicine Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Kidney Cancer Medicine Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Kidney Cancer Medicine Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Kidney Cancer Medicine Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Kidney Cancer Medicine Product Offerings
Table 32. Pfizer Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 33. Bristol-Myers Squibb Corporate Summary
Table 34. Bristol-Myers Squibb Kidney Cancer Medicine Product Offerings
Table 35. Bristol-Myers Squibb Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 36. Roche Corporate Summary
Table 37. Roche Kidney Cancer Medicine Product Offerings
Table 38. Roche Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 39. GSK Corporate Summary
Table 40. GSK Kidney Cancer Medicine Product Offerings
Table 41. GSK Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 42. Novartis Corporate Summary
Table 43. Novartis Kidney Cancer Medicine Product Offerings
Table 44. Novartis Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 45. Bayer Corporate Summary
Table 46. Bayer Kidney Cancer Medicine Product Offerings
Table 47. Bayer Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 48. Merck & Co. Corporate Summary
Table 49. Merck & Co. Kidney Cancer Medicine Product Offerings
Table 50. Merck & Co. Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 51. Exelixis Corporate Summary
Table 52. Exelixis Kidney Cancer Medicine Product Offerings
Table 53. Exelixis Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 54. Takeda Corporate Summary
Table 55. Takeda Kidney Cancer Medicine Product Offerings
Table 56. Takeda Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 57. Eisai Corporate Summary
Table 58. Eisai Kidney Cancer Medicine Product Offerings
Table 59. Eisai Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 60. CTTQ Corporate Summary
Table 61. CTTQ Kidney Cancer Medicine Product Offerings
Table 62. CTTQ Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 63. AVEO Oncology Corporate Summary
Table 64. AVEO Oncology Kidney Cancer Medicine Product Offerings
Table 65. AVEO Oncology Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 66. Everest Pharm Corporate Summary
Table 67. Everest Pharm Kidney Cancer Medicine Product Offerings
Table 68. Everest Pharm Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 69. Cipla Corporate Summary
Table 70. Cipla Kidney Cancer Medicine Product Offerings
Table 71. Cipla Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 72. NATCO Corporate Summary
Table 73. NATCO Kidney Cancer Medicine Product Offerings
Table 74. NATCO Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 75. Beacon Pharma Corporate Summary
Table 76. Beacon Pharma Kidney Cancer Medicine Product Offerings
Table 77. Beacon Pharma Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)
Table 78. SAMARTH Corporate Summary
Table 79. SAMARTH Kidney Cancer Medicine Product Offerings
Table 80. SAMARTH Kidney Cancer Medicine Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Kidney Cancer Medicine Segment by Type in 2021
Figure 2. Kidney Cancer Medicine Segment by Application in 2021
Figure 3. Global Kidney Cancer Medicine Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Kidney Cancer Medicine Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Kidney Cancer Medicine Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Kidney Cancer Medicine Revenue in 2021
Figure 8. By Type - Global Kidney Cancer Medicine Revenue Market Share, 2017-2028
Figure 9. By Application - Global Kidney Cancer Medicine Revenue Market Share, 2017-2028
Figure 10. By Region - Global Kidney Cancer Medicine Revenue Market Share, 2017-2028
Figure 11. By Country - North America Kidney Cancer Medicine Revenue Market Share, 2017-2028
Figure 12. US Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Kidney Cancer Medicine Revenue Market Share, 2017-2028
Figure 16. Germany Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 17. France Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Kidney Cancer Medicine Revenue Market Share, 2017-2028
Figure 24. China Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 28. India Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Kidney Cancer Medicine Revenue Market Share, 2017-2028
Figure 30. Brazil Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Kidney Cancer Medicine Revenue Market Share, 2017-2028
Figure 33. Turkey Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Kidney Cancer Medicine Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol-Myers Squibb Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Roche Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. GSK Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Novartis Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bayer Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Merck & Co. Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Exelixis Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Takeda Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Eisai Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. CTTQ Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. AVEO Oncology Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Everest Pharm Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Cipla Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. NATCO Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Beacon Pharma Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. SAMARTH Kidney Cancer Medicine Revenue Year Over Year Growth (US$, Mn) & (2017-2022)